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Introduction:
The focus of this study is to see if recently discharged psychiatric inpatients will have better treatment adherence and subsequently clinical outcomes as a result of having their medications placed into blister packs as opposed to standard pill bottle packaging. Previous research supports a range of benefits to blister packaging medications for at-risk patients (Liorca, 2008; Bosworth et.al., 2005; Dolder, Lacro, &.Jeste, 2003) . Non-adherence, defined ·as "not having a prescription filled, not taking enough medication, taking too much medication, not observing the correct interval between doses, not observing the correct duration of treatment and taking additional non-prescribed medication" (Bosworth, Oddone, & Weinberger, 2005, p. 149) , is a significant issue for those with psychiatric illness.
Moreover, studies suggest that psychiatric symptoms interfere with adherence and partial adherence is associated with poorer psychiatric outcomes, including suicide. Specifically, those who are non-adherent are at 4-7 times greater risk of death (Liorca, 2008) . Blister packaging, a structured means of dispensing medications (Bosworth etal., 2005 ) is expected to increase adherence, and decrease subsequent poor outcomes in the high risk population of psychiatric 'inpatients. Furthermore, this relatively simple intervention can be accomplished in any treatment setting and does not require any specialized training on the part of those administering the program. The specific aims of this study are to: examine if blister' packaging medication significantly increases medication adherence; determine if Blister Packaging .. 
Body:

Statement of Work
Task 1. Project Start-up (months 1-3) Completed la. Hire research assistant, pharmacy technician, and pharmacist (month 1)
• · All study personnel were hired by January 2010 (month 4) lb. Train staff (month 2)
• All study personnel were trained by April 2010 (month 7) lc. Orient inpatient staff to study logistics (month 3)
• Accomplished by month 7
Task 2. Participant recruitment (months 4-27) in progress: 2a.lntroducing·study to appropriate patients being discharged from the psychiatric inpatient unit at the Denver VA Medical Center (VAMC) (months 4-27) • Participant recruitment began in month 9 '2b.Securing consent to participate (months • Participant consent process began in month 9 2c. Recording contact information (months • Participant contact information collected and recorded immediately after consent signed; begun in month 9 2d.Creating participant data base (month 4) 21Page
• The master database was set up in month 6 Task 3. Baseline assessment (months 4-27} in progress:
3a.Administering assessment protocol to all participants prior to discharge from hospital (months 4-27} · • Baseline assessments began in month 9 3b. Creating assessment data base (month 4}
• The database was set up in month 6. 3c. Entering baseline assessment data (months 4-27}
• Process begun in month 9
Task 4. Preparing year one quarterly reports (months 3, 6, 9, 12} completed
• We submitted our 1st and 2nd quarterly reports and were exempt from the 3rd.
Task 5. Follow-up assessments (months 5-39} in progress:
Sa. Making phone calls to administer follow-up protocols to each participant at one month intervals post-discharge (months. S-39}
• A feasibility phase was added to the protocol and initiated in month 9. Five participants were recruited, but one dropped out. Follow-up assessm~nts by phone were conducted at 2 and 4 weeks post-discharge. Only one of these participants. completed both assessments. The others did not return phone calls, had pharmacy issues, or were readmitted to the hospital. As a result, a second feasibility phase to address these identified challenges was added in month 11 and is pending locaiiRB approval. Sb.Mailing checks or making checks available to participants following each completed assessment phone call (months S-39} • Checks were mailed beginning in month 9. Sc. Reviewing participants' VA medical records for clinic visits and in-patient admissions on a monthly basis (months S-39} • Initiated in month 9. · · Sd.Entering follow-up assessment data (months S-39}
• Initiated in month 10. Se.Checking entered data against raw data (months 9, 13, 17, 21, 2S, 29, 33, 37, 39} • Initiated in month 10. Sf. Correcting data entry errors identified in 5e (months 10, 14, 18, 22, 26, 30, 34, 38, 40} • Initiated in month 11.
Task 6. Preparing year two quarterly reports (months lS, 18, 21, 24) The initial feasibilityphase resulted in a number of changes to the study protocol, all of which have been approved by local regulatory bodies as well as HRPO. Problems with the pharmacy's packaging and dispensing of medications also needed to be addressed. Specifically, the original procedures did not allow enough time to accomplish these tasks prior to patient discharge. Changes made in communication flow now allow the pharmacy adequate time to package an initial 2-week or one month supply (second feasibility phase vs. full trial) of their prescribed medications. Participants are then sent home with a pre-paid envelope in which they are to return all old prescriptions to the pharmacy. After making these changes, we decided that it would be important to test out our new procedures and processes by adding a second feasibility phase and extending it to an additional 20 participants. Although this second feasibility phase will make the timeframe before full recruitment begins longer than anticipated, we believe that.it is justifiable.
In the most recent amendment, we added the Denver Research Institute to the current HIPAA B form because they will be receiving participant's PHI in order to send out checks for partidpant payments. We also listed the Safe Vet and Lithium studies as exclusionary criteria· for our study; these two studies are also investigational, therefore we cannot have participants overlap in these studies; In addition, several of the forms that the locaiiRB review group, COMIRB; uses have been updated, so we updated our documents so that they are consistent with the current versions. We are removing Dr.
Rings as a study coordinator because his fellowship ended and he left the VA.
Recruiting participants for the full-phase trial of the study is underway as is baseline and followup assessment.
Key Research Accomplishments:
• Finished recruiting participants for the feasibility phase of the study.
• Recognized important procedural issues that would be helpful to fix and received regulatory approval on these minor modifications.
• Began recruiting for the full-phase trial of the _study.
• Baseline and follow-up assessments underway. ABSTRACT:
Medication overdoses account for substantial numbers of cases of self-directed violence (SDV} in several segments of the United States (US} population. The purpose of the study described in this chapter is to determine if medication administration via blister packaging is associated with an increase in treatment adherence and a decrease in intentional overdoses among a high risk population of patients either discharged from psychiatric inpatient units or receiving care in outpatient mental health or substance abuse clinics. As such the research aims ofthe project to be described are as follows: 1) To explore whether blister packaging medication decreases overall symptom distress; 2) To explore whether blister packaging medication reduces additional negative medical and psychiatric outcomes (e.g., emergency department admissions, psychiatric hospitalizations); and 3} To explore whether blister packaging medication reduces health care utilization (e.g., clinic visits). If hypotheses are supported, findings from this study will provide evidence that this means of dispensing prescription medications decreases suicide risk through two mechanisms. SpeCifically, it is expected that increasing adherence will result in a decrease in symptoms reported aswell as overall psychological distress. This alone would be expected to decrease an individual's suicide risk. Also, creating appropriate means restriction should result in reduced morbidity and mortality resulting from intentional and accidental overdoses. The theoretical and empirical background, rationale, methods, and measures described in this chapter should help clinicians to appreciate the potential utility of blister packaging medications for their high-risk patients and provide researchers with a promising line of study in the realm of suicide means restriction.
Conclusion:
Participant recruitment for the feasibility phase ofthe clinical trial is complete.
Necessary changes to the protocol based on those findings have been made and approved by all regulatory bodies. Full trial recruitment and data collection are underway. Interest from the field in the project is strong, and information about this work is being disseminated.
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